Innoviva, Inc. (INVA)
NASDAQ: INVA · IEX Real-Time Price · USD
17.19
+0.08 (0.47%)
At close: Jul 19, 2024, 4:00 PM
17.21
+0.02 (0.12%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Innoviva Revenue
Innoviva had revenue of $311.59M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $77.50M with 1.48% year-over-year growth. In the year 2023, Innoviva had annual revenue of $310.46M.
Revenue (ttm)
$311.59M
Revenue Growth
-1.91%
P/S Ratio
3.45
Revenue / Employee
$2,782,054
Employees
112
Market Cap
1.07B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 310.46M | -20.88M | -6.30% |
Dec 31, 2022 | 331.34M | -60.53M | -15.45% |
Dec 31, 2021 | 391.87M | 55.07M | 16.35% |
Dec 31, 2020 | 336.79M | 75.78M | 29.03% |
Dec 31, 2019 | 261.02M | 12.00K | 0.00% |
Dec 31, 2018 | 261.00M | 43.79M | 20.16% |
Dec 31, 2017 | 217.22M | 83.65M | 62.63% |
Dec 31, 2016 | 133.57M | 79.62M | 147.58% |
Dec 31, 2015 | 53.95M | 45.52M | 539.74% |
Dec 31, 2014 | 8.43M | 3.90M | 86.08% |
Dec 31, 2013 | 4.53M | -1.08M | -19.26% |
Dec 31, 2012 | 5.61M | -18.90M | -77.10% |
Dec 31, 2011 | 24.51M | 289.00K | 1.19% |
Dec 31, 2010 | 24.22M | -151.00K | -0.62% |
Dec 31, 2009 | 24.37M | 1.28M | 5.53% |
Dec 31, 2008 | 23.10M | 1.09M | 4.97% |
Dec 31, 2007 | 22.00M | 2.42M | 12.33% |
Dec 31, 2006 | 19.59M | 7.53M | 62.49% |
Dec 31, 2005 | 12.05M | 3.11M | 34.83% |
Dec 31, 2004 | 8.94M | 5.34M | 147.99% |
Dec 31, 2003 | 3.61M | 3.45M | 2,210.90% |
Dec 31, 2002 | 156.00K | - | - |
Dec 31, 2001 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.42B |
Collegium Pharmaceutical | 566.92M |
Ironwood Pharmaceuticals | 413.55M |
Artivion | 368.21M |
MiMedx Group | 334.51M |
Silk Road Medical | 185.49M |
Calliditas Therapeutics AB (publ) | 119.73M |
Arcutis Biotherapeutics | 106.39M |
INVA News
- 4 weeks ago - Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs - Benzinga
- 6 weeks ago - Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 2 months ago - Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress - Business Wire
- 2 months ago - Innoviva to Participate in the BofA Securities Health Care Conference - Business Wire
- 3 months ago - Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 - Business Wire
- 4 months ago - Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 5 months ago - Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress - Business Wire
- 5 months ago - 10 stocks you can bet on being inflation-proof - Market Watch